NPS Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

BEDMINSTER, N.J.--(BUSINESS WIRE)-- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 14, 2011 at 10:20 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors’ calendar of events page on the NPS website at http://www.npsp.com/events.

About NPS Pharmaceuticals

NPS Pharmaceuticals is an outsourcing-based development company focused on bringing biopharmaceuticals to patients with rare disorders and few, if any, therapeutic options. The company is advancing two Phase 3 registration programs, GATTEX® (teduglutide) in short bowel syndrome (SBS) and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) in hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical.



CONTACT:

NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335

KEYWORDS:   United States  North America  Canada  New Jersey  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.